secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001193125-22-064445
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic appoints Michael Jensen as CFO effective March 3, 2022
---------------------------------------------------------------

- Michael Jensen named CFO; previously CFO at Intrinsic Therapeutics and Taconic Biosciences.
- Base salary $395K, bonus target 40%, option grant of 230K shares at $2.23, 30K RSUs.
- Employment agreement provides 6-month severance upon termination without cause or for good reason.
- Press release notes Synlogic on track to start Phase 3 study for PKU in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/0001193125-22-064445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522064445/d291506d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-064445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer